

Mirella Giovarelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5935474/publications.pdf>

Version: 2024-02-01

89
papers

4,566
citations

81900

39
h-index

102487

66
g-index

89
all docs

89
docs citations

89
times ranked

5633
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.8	326
2	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	8.5	291
3	Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. <i>Frontiers in Immunology</i> , 2017, 8, 1097.	4.8	208
4	Cytokines, tumour-cell death and immunogenicity: a question of choice. <i>Trends in Immunology</i> , 1997, 18, 32-36.	7.5	161
5	Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1049-1058.	6.3	158
6	Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of Interleukin-2 injected periilymphatically. <i>Cancer</i> , 1988, 62, 2482-2485.	4.1	146
7	Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. <i>Diabetologia</i> , 2016, 59, 325-333.	6.3	139
8	Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. <i>Immunobiology</i> , 2008, 213, 733-749.	1.9	138
9	Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. <i>FASEB Journal</i> , 2008, 22, 2747-2757.	0.5	120
10	Circulating Autoantibodies to Phosphorylated α -Enolase are a Hallmark of Pancreatic Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 105-112.	3.7	119
11	Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. <i>Blood</i> , 2011, 117, 2625-2639.	1.4	119
12	Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. <i>Diabetologia</i> , 2014, 57, 1664-1673.	6.3	119
13	An integrated humoral and cellular response is elicited in pancreatic cancer by α -enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. <i>International Journal of Cancer</i> , 2009, 125, 639-648.	5.1	115
14	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1098-1106.	1.3	104
15	Transcriptome of Hypoxic Immature Dendritic Cells: Modulation of Chemokine/Receptor Expression. <i>Molecular Cancer Research</i> , 2008, 6, 175-185.	3.4	94
16	Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice. <i>Nature</i> , 1983, 306, 181-184.	27.8	89
17	Inhibition of tumor growth and enhancement of metastasis after transfection of the β -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	5.1	89
18	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. <i>Journal of Proteome Research</i> , 2007, 6, 4025-4031.	3.7	88

#	ARTICLE	IF	CITATIONS
19	Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1472-1482.	3.3	88
20	CCL16 activates an angiogenic program in vascular endothelial cells. <i>Blood</i> , 2004, 103, 40-49.	1.4	85
21	Tumor Rejection and Immune Memory Elicited by Locally Released LEC Chemokine Are Associated with an Impressive Recruitment of APCs, Lymphocytes, and Granulocytes. <i>Journal of Immunology</i> , 2000, 164, 3200-3206.	0.8	83
22	Survival and Migration of Human Dendritic Cells Are Regulated by an IFN- γ -Inducible Axl/Gas6 Pathway. <i>Journal of Immunology</i> , 2009, 183, 3004-3013.	0.8	78
23	<i>In Vitro&/i> and <i>In Vivo&/i> Therapeutic Evaluation of Camptothecin-Encapsulated <i>P&/i>-Cyclodextrin Nanosponges in Prostate Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 114-127.	1.1	67
24	LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. <i>Cancer Research</i> , 2003, 63, 2518-25.	0.9	67
25	Role of dendritic cell-derived CXCL13 in the pathogenesis of <i>Bartonella henselae</i> B-rich granuloma. <i>Blood</i> , 2006, 107, 454-462.	1.4	65
26	The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. <i>Experimental Cell Research</i> , 2004, 293, 331-345.	2.6	60
27	Interferon- β is not an antiviral, but a growth-promoting factor for T lymphocytes. <i>European Journal of Immunology</i> , 1988, 18, 503-510.	2.9	59
28	Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. <i>Cancer and Metastasis Reviews</i> , 1988, 7, 289-309.	5.9	59
29	The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. <i>Immunobiology</i> , 2013, 218, 76-89.	1.9	59
30	Pro-Inflammatory Profile of Preeclamptic Placental Mesenchymal Stromal Cells: New Insights into the Etiopathogenesis of Preeclampsia. <i>PLoS ONE</i> , 2013, 8, e59403.	2.5	59
31	Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. <i>Head and Neck</i> , 1991, 13, 125-131.	2.0	50
32	Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and $TREM1$ expression. <i>European Journal of Immunology</i> , 2013, 43, 949-966.	2.9	49
33	IGF-1 down-regulates IFN- β R2 chain surface expression and desensitizes IFN- β /STAT-1 signaling in human T lymphocytes. <i>Blood</i> , 2003, 102, 2933-2939.	1.4	45
34	Sulfated K5 <i>Escherichia coli</i> Polysaccharide Derivatives as Wide-Range Inhibitors of Genital Types of Human Papillomavirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1374-1381.	3.2	43
35	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. <i>Journal of Hematology and Oncology</i> , 2013, 6, 67.	17.0	42
36	Activin A Induces Langerhans Cell Differentiation In Vitro and in Human Skin Explants. <i>PLoS ONE</i> , 2008, 3, e3271.	2.5	41

#	ARTICLE	IF	CITATIONS
37	Human Mesenchymal Stem Cells Modulate Cellular Immune Response to Islet Antigen Glutamic Acid Decarboxylase in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3788-3797.	3.6	41
38	The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. <i>Journal of Autoimmunity</i> , 2010, 35, 114-123.	6.5	41
39	Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells <i>in vitro</i> and <i>in vivo</i> on orthotopic xenograft tumors. <i>Drug Delivery</i> , 2017, 24, 670-680.	5.7	41
40	Iron regulates T-lymphocyte sensitivity to the IFN- β /STAT1 signaling pathway <i>in vitro</i> and <i>in vivo</i> . <i>Blood</i> , 2005, 105, 3214-3221.	1.4	40
41	B7h Triggering Inhibits the Migration of Tumor Cell Lines. <i>Journal of Immunology</i> , 2014, 192, 4921-4931.	0.8	40
42	Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. <i>Journal of Pathology</i> , 2005, 205, 82-91.	4.5	39
43	Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor. <i>Journal of Immunology</i> , 2004, 172, 4026-4036.	0.8	38
44	CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2004, 75, 135-142.	3.3	37
45	Production and function of activin A in human dendritic cells. <i>European Cytokine Network</i> , 2008, 19, 60-8.	2.0	36
46	The interferon-inducible gene IFI16 secretome of endothelial cells drives the early steps of the inflammatory response. <i>European Journal of Immunology</i> , 2010, 40, 2182-2189.	2.9	32
47	Tumor Immunotherapy by Local Injection of Interleukin 2 and Non-Reactive Lymphocytes. <i>Progress in Tumor Research</i> , 1988, 32, 187-212.	0.1	29
48	Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2013, 190, 1125-1134.	0.8	28
49	Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1486-1498.	3.4	25
50	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2910-2921.	7.0	24
51	Lymphokine production in mouse mixed lymphocyte reaction (MLR). <i>Immunogenetics</i> , 1979, 9, 245-253.	2.4	23
52	The macrophage as the social interconnection within the immune system. <i>Developmental and Comparative Immunology</i> , 1980, 4, 11-19.	2.3	22
53	CC-Chemokine Ligand 16 Induces a Novel Maturation Program in Human Immature Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 6143-6151.	0.8	21
54	Death Receptor Ligands in Tumors. <i>Journal of Immunotherapy</i> , 2002, 25, 1-15.	2.4	20

#	ARTICLE	IF	CITATIONS
55	In the absence of IGF-1 signaling, IFN- β suppresses human malignant T-cell growth. <i>Blood</i> , 2007, 109, 2496-2504.	1.4	20
56	Anti- α -enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response. <i>Onc Immunology</i> , 2016, 5, e1112940.	4.6	19
57	H-2-restriction and Ia-dependence of the efficient immune recognition of minor histocompatibility antigens in vivo. <i>Immunogenetics</i> , 1979, 9, 199-202.	2.4	18
58	Immune recognition of tumor cells in vivo. I. Role of H-2 gene products in T lymphocyte activation against minor histocompatibility antigens displayed by adenocarcinoma cells. <i>European Journal of Immunology</i> , 1982, 12, 664-670.	2.9	15
59	Lack of Plasma Protein Hemopexin Dampens Mercury-Induced Autoimmune Response in Mice. <i>Journal of Immunology</i> , 2008, 181, 1937-1947.	0.8	15
60	Modulation of interferon- β receptor during human T lymphocyte alloactivation. <i>European Journal of Immunology</i> , 1993, 23, 1226-1231.	2.9	14
61	Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. <i>Pancreas</i> , 2014, 43, 1066-1072.	1.1	14
62	Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. , 1998, 186, 390-397.		13
63	Strategies for cell-mediated immunotherapy of cancer: killing or help?. <i>Trends in Immunology</i> , 1986, 7, 202-203.	7.5	12
64	Expression of IFN- β R2 mutated in a dileucine internalization motif reinstates IFN- β signaling and apoptosis in human T lymphocytes. <i>Immunology Letters</i> , 2010, 134, 17-25.	2.5	12
65	Suppressor macrophages in tumor-bearing mice. Inconsistency between in vivo and in vitro findings?. <i>International Journal of Cancer</i> , 1982, 29, 695-698.	5.1	10
66	Lymphokine-activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon- β injected around tumor-draining lymph nodes. <i>International Journal of Cancer</i> , 1989, 44, 62-65.	5.1	10
67	Regulation of Langerhans cell functions in a hypoxic environment. <i>Journal of Molecular Medicine</i> , 2016, 94, 943-955.	3.9	10
68	Release of interleukin-2-like material by b-chronic lymphocytic leukemia cells. An autocrine or paracrine model of production and utilization?. <i>Leukemia Research</i> , 1988, 12, 201-209.	0.8	9
69	Low Levels of Urinary PSA Better Identify Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 3570.	3.7	9
70	Exploring chitosan-shelled nanobubbles to improve HER2+ immunotherapy via dendritic cell targeting. <i>Drug Delivery and Translational Research</i> , 2022, 12, 2007-2018.	5.8	8
71	Physiological and pathological influences of central nervous system on the immune system: A critical appraisal. <i>Journal of Psychiatric Research</i> , 1984, 18, 491-499.	3.1	7
72	In vitro arming and blocking activity of sera from BALB/c mice bearing a spontaneous transplantable adenocarcinoma. <i>European Journal of Cancer</i> , 1977, 13, 1217-1223.	0.9	6

#	ARTICLE	IF	CITATIONS
73	DISTINCT ALLOANTIGENS TRIGGER PROLIFERATIVE OR NONPROLIFERATIVE T LYMPHOCYTE ACTIVATION IN CBA/N, CBA/J, AND C3H MICE. <i>Transplantation</i> , 1982, 33, 260-264.	1.0	6
74	In vitro and in vivo immunomodulatory activity of an N-9 arginyl hypoxanthine derivative (PCF-39). <i>International Journal of Immunopharmacology</i> , 1987, 9, 659-667.	1.1	6
75	Strategies for cytokine utilisation in tumor therapy. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1993, 10, 53-59.	1.1	6
76	Rous sarcoma virus-induced tumors in mice. Macrophage-mediated natural cytotoxicity. <i>European Journal of Cancer & Clinical Oncology</i> , 1982, 18, 307-315.	0.7	5
77	MATCHING FOR HLA-DR ANTIGENS IN RENAL TRANSPLANTATION. <i>Transplantation</i> , 1979, 27, 288-290.	1.0	4
78	B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 329-337.	3.8	4
79	Lymphokine-Activated Tumor Inhibition (LATI) in Vivo. , 1987, , 335-360.		4
80	Is antibody-dependent cellular cytotoxicity an important mechanism of resistance to tumors in vivo?. <i>Immunochemistry</i> , 1978, 15, 801-805.	1.2	3
81	Macrophages expressing TREM-1 are involved in the progression of HPV16-related oropharyngeal squamous cell carcinoma. <i>Annals of Medicine</i> , 2021, 53, 541-550.	3.8	3
82	Enhancement versus tumor resistance induced by different levels of immunodepression in BALB/c mice with protozoan infections. <i>European Journal of Cancer</i> , 1979, 15, 27-33.	0.9	2
83	Evolution of macrophage immune recognition of viral, bacterial, protozoal and allo-antigens. <i>Developmental and Comparative Immunology</i> , 1981, 5, 61-66.	2.3	2
84	Cytokines and Tumor Immunogenicity. , 1998, , 231-247.		1
85	In Vivo Requirements for the Immune Recognition of L1210 Leukemia Cells by Allogeneic T-Lymphocytes. <i>Tumori</i> , 1983, 69, 403-408.	1.1	0
86	IL-2 and Lymphocytes from Tumor Bearing Mice: A Combinatory Immunotherapy of Tumors. , 1984, , 159-173.		0
87	Interleukin 2: In Vivo Induction of Effector Cells. , 1990, , 37-46.		0
88	Tumour Immunogenicity Induced by Exogenous Interleukins. , 1992, , 29-35.		0
89	Tumor Immunogenicity Induced by the Local Occurrence of Il-2. , 1993, , 31-37.		0